New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
11:05 EDTRGP, CMLP, JNS, ALIM, IRWD, WYN, TPH, DMND, JE, BKDHigh option volume stocks
High option volume stocks: ALIM BKD TPH JNS JE WYN CMLP DMND IRWD RGP
News For ALIM;BKD;TPH;JNS;JE;WYN;CMLP;DMND;IRWD;RGP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
20:03 EDTWYNWyndham management to meet with JPMorgan
Subscribe for More Information
14:04 EDTJNSBill Gross to manage $500M fund for Soros Management
Subscribe for More Information
09:02 EDTIRWDIronwood earns $15M milestone from Astellas Pharma
Ironwood Pharmaceuticals has earned a $15M development milestone payment from Astellas Pharma Inc., its partner for linaclotide in Japan. This milestone was triggered by Astellasís enrollment of the first patient in a randomized, double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with irritable bowel syndrome with constipation in Japan. Astellas expects to complete the Phase III trial in 2016. Ironwood and Astellas entered into a licensing agreement in 2009 to develop and commercialize linaclotide in Japan for the treatment of IBS-C, chronic constipation and other gastrointestinal conditions. Per the agreement, Astellas paid Ironwood a $30M upfront licensing fee. In addition to the $15M development milestone payment upon enrollment of the first patient in the Phase III trial, the agreement also includes additional development milestone payments that could total up to $30M, consisting of $15M upon filing for regulatory approval in Japan and $15M upon receipt of approval. The agreement also provides for Ironwood to receive royalties which escalate based on sales volume. Astellas also plans to expand its development of linaclotide in Japan and is entering into a Phase II clinical trial with linaclotide in adults with chronic constipation. If approved, the same royalty terms would apply.
November 17, 2014
14:01 EDTRGPTalisman in talks to sell Marcellus pipelines valued at over $1B, Bloomberg says
Subscribe for More Information
11:46 EDTALIMAlimera Sciences' ILUVIEN receives marketing approval in Ireland
Subscribe for More Information
10:02 EDTALIMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:55 EDTALIMAlimera Sciences initiated with a Buy at Summer Street
Target $12.
08:05 EDTRGPEnergy Transfer Partners, Regency Energy Partners to construct NGL pipeline
Subscribe for More Information
07:19 EDTBKDBrookdale Senior Living should be bought at current levels, says JMP Securities
JMP Securities believes that worries over Brookdale's 70 basis point, year-over-year drop in Q3 same-store occupancy were overdone. The firm thinks the company''s Q3 results were solid overall, and it reiterates a $46 price target on the shares.
November 14, 2014
11:02 EDTTPHTRI Pointe Homes to host analyst and investor day
Subscribe for More Information
November 13, 2014
17:10 EDTTPHTRI Pointe Homes files automatic common stock shelf for holders
Subscribe for More Information
07:01 EDTBKDBrookdale Senior Living removed from short-term buy list at Deutsche Bank
Subscribe for More Information
November 12, 2014
07:43 EDTALIMAlimera Sciences' Iluvien receives marketing authorization in Belgium
Alimera Sciences,announced that the Belgian Federal Agency for Medicines and Health Products has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. Approval in Belgium marks the fourth European approval through the Repeat-Use application procedure and the 12th approval worldwide, including the recent U.S. approval for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. To date, ILUVIEN is now approved for marketing in Austria, Belgium, Denmark, France, Germany, Italy, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States, and is commercially available in the United Kingdom and Germany. ILUVIEN is pending approval in an additional six European Union countries included in the Repeat-Use application procedure. These countries are the Czech Republic, Finland, Ireland, Luxembourg, the Netherlands and Poland.
November 11, 2014
07:56 EDTJNSJanus Capital inflows accelerated in October, says Jefferies
Subscribe for More Information
07:02 EDTJNSJanus Capital fund flows tracking well below consensus, says Citigroup
After Bloomberg reported that Janus saw $1.2B in October bond fund inflows, Citigroup says the company's new business trends are tracking "sharply below those implied in the stock price." Citi believes Janus' flow trends are tracking in-line with its "well below" consensus 2015-16 earnings estimates. It keeps a Sell rating on Janus with a $12.50 price target.
November 10, 2014
08:30 EDTJNSJanus funds saw over $1B in inflows after Gross hiring, Bloomberg says
Subscribe for More Information
07:08 EDTIRWDbluebird bio names James DeTore as CFO, treasurer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use